| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
179,708 |
142,784 |
$8.67M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
104,236 |
85,486 |
$6.83M |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
412,749 |
166,400 |
$2.82M |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
146,183 |
116,534 |
$2.39M |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
169,485 |
138,200 |
$1.44M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
24,062 |
18,533 |
$1.05M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
50,078 |
38,343 |
$836K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
20,485 |
15,579 |
$679K |
| 87634 |
|
22,429 |
18,409 |
$653K |
| 87807 |
|
33,298 |
26,879 |
$225K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
42,954 |
33,861 |
$218K |
| 99051 |
|
16,792 |
14,661 |
$57K |
| 99215 |
Prolong outpt/office vis |
785 |
482 |
$42K |
| 81003 |
|
12,447 |
10,165 |
$20K |
| 71046 |
Radiologic examination, chest; 2 views |
848 |
694 |
$14K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
29,491 |
23,588 |
$13K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
367 |
309 |
$13K |
| 87631 |
|
378 |
314 |
$8K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
7,815 |
6,151 |
$7K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
986 |
775 |
$7K |
| 80305 |
|
995 |
644 |
$5K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
6,517 |
4,251 |
$5K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
183 |
158 |
$4K |
| 90473 |
|
1,216 |
1,076 |
$3K |
| 99000 |
|
6,333 |
4,700 |
$3K |
| 99205 |
Prolong outpt/office vis |
37 |
25 |
$3K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
5,104 |
4,070 |
$3K |
| 87809 |
|
433 |
369 |
$2K |
| 81025 |
|
1,128 |
888 |
$2K |
| 86308 |
|
378 |
290 |
$579.96 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
21 |
19 |
$410.59 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
583 |
474 |
$403.81 |
| 86318 |
|
53 |
29 |
$164.92 |
| 74018 |
|
19 |
12 |
$122.29 |
| 82947 |
|
32 |
24 |
$56.00 |
| 36415 |
Collection of venous blood by venipuncture |
108 |
78 |
$38.40 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
48 |
34 |
$34.02 |
| 3074F |
|
21,994 |
17,589 |
$0.00 |
| 3079F |
|
5,491 |
4,387 |
$0.00 |
| 3075F |
|
513 |
375 |
$0.00 |
| 3080F |
|
463 |
343 |
$0.00 |
| A9150 |
Non-prescription drugs |
27 |
26 |
$0.00 |
| 3078F |
|
10,721 |
8,431 |
$0.00 |
| J7510 |
Prednisolone oral, per 5 mg |
448 |
327 |
$0.00 |
| 3077F |
|
821 |
603 |
$0.00 |
| J7614 |
Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg |
41 |
25 |
$0.00 |
| G8483 |
Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) |
24 |
19 |
$0.00 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
17 |
12 |
$0.00 |